Modelling hepatitis C virus infection and the development of hepatocellular carcinoma

Journal of Theoretical Biology
Siddhartha P Chakrabarty, John M Murray

Abstract

While mathematical models exist describing the dynamics of hepatitis C virus (HCV), most of them focus on the short term dynamics after the commencement of antiviral therapy. This work is the first attempt at mathematically modelling the full course of HCV infection and the impact that these viral and immune processes have on the progression to hepatocellular carcinoma (HCC). This model is based on the premise that these long term conditions are ultimately random and likely driven by the cell-mediated immune response. The risk of cancer arising is modelled through a stochastic model that incorporates the dynamics of HCV over the course of infection. Our model simulations produce approximately 9% prevalence of HCC in individuals after 40 years, consistent with the literature estimates. We find that higher viral infectivity leads to a greater likelihood of developing HCC (p<0.0001), but it does not determine the speed with which it arises. This infectivity drives the level of immune response, the amount of hepatocyte proliferation, and the risk of a mutational event. In our simulations the probability of developing HCC increases approximately linearly with duration of infection at the rate of 2.4 incident cases per thousand HCV-i...Continue Reading

References

Nov 15, 1991·Science·M A NowakR M May
Apr 5, 1996·Science·M A Nowak, C R Bangham
Feb 3, 2000·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·M H KhanC Liddle
Nov 21, 2001·The Journal of Experimental Medicine·R ThimmeF V Chisari
Mar 1, 2002·Immunology and Cell Biology·Ian R Mackay
Jun 18, 2003·The Journal of General Virology·Dominik Wodarz
Oct 9, 2004·HIV Clinical Trials·Marina Núñez, Vincent Soriano
Mar 2, 2005·Nature Reviews. Immunology·Barbara Rehermann, Michelina Nascimbeni
Jun 18, 2005·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Andrea L CoxStuart C Ray
Feb 1, 2006·Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·Kimberly A PowersAlan S Perelson
Mar 16, 2007·Proceedings of the National Academy of Sciences of the United States of America·Stanca M CiupeAlan S Perelson
Apr 25, 2007·Journal of Theoretical Biology·Harel DahariAlan S Perelson
Aug 3, 2007·Drug and Alcohol Dependence·Karina RazaliMatthew Law
Nov 21, 2007·Journal of Viral Hepatitis·W S MasonA R Jilbert
Oct 22, 2008·Expert Reviews in Molecular Medicine·Barbara Roe, William W Hall
Feb 12, 2009·Journal of Biosciences·Ashis Mukhopadhyaya
Nov 17, 2009·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Giuseppe CastelloFrancesco Izzo
Mar 17, 2010·Oncogene·W-L Tsai, R T Chung

❮ Previous
Next ❯

Citations

Mar 11, 2015·Journal of Clinical and Experimental Hepatology·Ashish KumarUNKNOWN (The INASL Task-Force on Hepatocellular Carcinoma)
Feb 15, 2019·International Journal of Environmental Research and Public Health·Markus M KnodelGabriel Wittum

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.

Adrenocortical Carcinoma

Hepatocellular carcinoma is the most common type of primary liver cancer and frequently occurs in individuals with chronic liver diseases like cirrhosis. Here is the latest research.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

HIV/AIDS-Related Malignancies

HIV/AIDS infection increases the risk of non-communicable diseases common in the aged including HIV/AIDS-related malignancies. Discover the latest research in HIV/AIDS-related malignancies.